BACKGROUND AND OBJECTIVES: Hyperuricemia is associated with hypertension, coronary artery disease, and chronic kidney disease. However, there are no specific data on the relationship of uric acid to cardiovascular disease in the chronic hemodialysis setting. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data from 5827 patients on chronic hemodialysis from six countries affiliated with the Dialysis Outcomes and Practice Patterns Study (DOPPS) were analyzed. All laboratory data were based upon the initial cross-section of patients in DOPPS I and II. Cox regression was used to calculate the hazard ratio (HR) of all-cause and cardiovascular (CV) mortality with adjustments for case-mix including 14 classes of comorbidity. RESULTS: There were no clinically significant differences in baseline characteristics between those who had measured uric acid (n = 4637) and those who did not (n = 1190). Uric acid level was associated with lower all-cause mortality (HR: 0.95, 95% confidence interval [CI]: 0.90 to 1.00 per 1 mg/dl higher uric acid level) and CV mortality (HR: 0.92, 95% CI: 0.86 to 0.99). When analyzed as a dichotomous variable, the adjusted HR at uric acid ≤8.2 mg/dl compared with >8.2 mg/dl was 1.24 (95% CI: 1.03 to 1.49) for all-cause mortality and 1.54 (95% CI: 1.15 to 2.07) for CV mortality. CONCLUSIONS: Higher uric acid levels were associated with lower risk of all-cause and CV mortality in the hemodialysis population. These results are in contrast to the association of hyperuricemia with higher cardiovascular risk in the general population and should be the subject of further research.
BACKGROUND AND OBJECTIVES:Hyperuricemia is associated with hypertension, coronary artery disease, and chronic kidney disease. However, there are no specific data on the relationship of uric acid to cardiovascular disease in the chronic hemodialysis setting. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data from 5827 patients on chronic hemodialysis from six countries affiliated with the Dialysis Outcomes and Practice Patterns Study (DOPPS) were analyzed. All laboratory data were based upon the initial cross-section of patients in DOPPS I and II. Cox regression was used to calculate the hazard ratio (HR) of all-cause and cardiovascular (CV) mortality with adjustments for case-mix including 14 classes of comorbidity. RESULTS: There were no clinically significant differences in baseline characteristics between those who had measured uric acid (n = 4637) and those who did not (n = 1190). Uric acid level was associated with lower all-cause mortality (HR: 0.95, 95% confidence interval [CI]: 0.90 to 1.00 per 1 mg/dl higher uric acid level) and CV mortality (HR: 0.92, 95% CI: 0.86 to 0.99). When analyzed as a dichotomous variable, the adjusted HR at uric acid ≤8.2 mg/dl compared with >8.2 mg/dl was 1.24 (95% CI: 1.03 to 1.49) for all-cause mortality and 1.54 (95% CI: 1.15 to 2.07) for CV mortality. CONCLUSIONS: Higher uric acid levels were associated with lower risk of all-cause and CV mortality in the hemodialysis population. These results are in contrast to the association of hyperuricemia with higher cardiovascular risk in the general population and should be the subject of further research.
Authors: Ronald L Pisoni; Brenda W Gillespie; David M Dickinson; Kenneth Chen; Michael H Kutner; Robert A Wolfe Journal: Am J Kidney Dis Date: 2004-11 Impact factor: 8.860
Authors: Leo K Niskanen; David E Laaksonen; Kristiina Nyyssönen; Georg Alfthan; Hanna-Maaria Lakka; Timo A Lakka; Jukka T Salonen Journal: Arch Intern Med Date: 2004-07-26
Authors: Alfred K Cheung; Mark J Sarnak; Guofen Yan; Michael Berkoben; Robert Heyka; Allen Kaufman; Julia Lewis; Michael Rocco; Robert Toto; David Windus; Daniel Ornt; Andrew S Levey Journal: Kidney Int Date: 2004-06 Impact factor: 10.612
Authors: S M Kurt Lee; Andrew L Lee; Thomas J Winters; Emily Tam; Mohammed Jaleel; Peter Stenvinkel; Richard J Johnson Journal: Am J Nephrol Date: 2008-08-11 Impact factor: 3.754
Authors: Aud Høieggen; Michael H Alderman; Sverre E Kjeldsen; Stevo Julius; Richard B Devereux; Ulf De Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Cong Chen; Björn Dahlöf Journal: Kidney Int Date: 2004-03 Impact factor: 10.612
Authors: Yongmei Liu; Josef Coresh; Joseph A Eustace; J Craig Longenecker; Bernard Jaar; Nancy E Fink; Russell P Tracy; Neil R Powe; Michael J Klag Journal: JAMA Date: 2004-01-28 Impact factor: 56.272
Authors: Ozkan Gungor; Mehmet Tanrisev; Fatih Kircelli; Mehmet Nuri Turan; Cem Tugmen; Erhan Tatar; Huseyin Toz Journal: Int Urol Nephrol Date: 2012-06-30 Impact factor: 2.370
Authors: Abutaleb Ahsan Ejaz; Takahiko Nakagawa; Mehmet Kanbay; Masanari Kuwabara; Ada Kumar; Fernando E Garcia Arroyo; Carlos Roncal-Jimenez; Fumihiko Sasai; Duk-Hee Kang; Thomas Jensen; Ana Andres Hernando; Bernardo Rodriguez-Iturbe; Gabriela Garcia; Dean R Tolan; Laura G Sanchez-Lozada; Miguel A Lanaspa; Richard J Johnson Journal: Semin Nephrol Date: 2020-11 Impact factor: 5.299